ERNA•globenewswire•
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
Summary
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO).
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 27, 2026 by globenewswire